temozolomide has been researched along with Neuroendocrine Tumors in 94 studies
Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking." | 9.69 | Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. ( Amoroso, V; Berruti, A; Brizzi, MP; Colao, A; Faggiano, A; Fazio, N; Ferolla, P; Ghizzoni, S; Giuffrida, D; Houchard, A; Ibrahim, T; La Salvia, A; Marconcini, R; Mazzanti, P; Spada, F; Vaccaro, V; Volante, M, 2023) |
| "Abstract We conducted a phase I-II clinical trial to assess the safety and efficacy of combining lutetium-177 ((177)Lu)-octreotate with capecitabine and temozolomide in treating advanced low-grade neuroendocrine tumors (NETs)." | 9.16 | Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. ( Claringbold, PG; Price, RA; Turner, JH, 2012) |
| "Orally administered temozolomide and thalidomide seems to be an active regimen for the treatment of neuroendocrine tumors." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs)." | 8.31 | Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group. ( Ağdaş, G; Ak, N; Akay, B; Akyıldız, A; Alan, Ö; Arak, H; Aydınalp, Y; Azizy, A; Bayram, D; Bilgin, B; Büyükbayram, ME; Büyükşimşek, M; Çağlayan, M; Canaslan, K; Çetin, B; Çoban, E; Demirci, A; Derin, S; Dursun, B; Ercelep, Ö; Erdal, GŞ; Eryılmaz, MK; Evrensel, T; Göksu, SS; Gümüş, M; Güven, DC; Güzel, HG; Hendem, E; Kahvecioğlu, FA; Kalkan, Z; Karabulut, S; Karataş, F; Kefeli, U; Kılıçkap, S; Köş, FT; Ön, S; Ordu, Ç; Oruç, Z; Özçelik, M; Özdemir, N; Paksoy, N; Paydaş, S; Sağlam, S; Sakin, A; Salim, DK; Şanlı, UA; Selvi, O; Şendur, MAN; Sever, N; Seyyar, M; Şimşek, M; Taştekin, D; Tatlı, AM; Topçu, A; Turna, ZH; Uğraklı, M; Ünal, Ç; Ünek, İT; Ürün, Y; Uygun, K; Yalçın, Ş; Yaşar, S; Yazıcı, O; Yücel, KB, 2023) |
| "We evaluated outcomes of treatment with 5-fluorouracil (5-FU), doxorubicin, and streptozocin (FAS) in well-differentiated pancreatic neuroendocrine tumors (PanNETs) and its impact on subsequent therapy (everolimus or temozolomide)." | 8.12 | Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. ( Dagohoy, CG; Dasari, A; Halperin, DM; Lam, M; Rogers, JE; Yao, JC, 2022) |
| "The role of alternate sequential administration of sunitinib and capecitabine/temozolomide (CAPTEM) in metastatic pancreatic neuroendocrine tumors (PanNETs) remains unexplored." | 8.12 | Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors. ( Dong, J; Gao, H; Li, H; Liu, L; Ni, Q; Wang, W; Xu, H; Ye, L; Zhang, W, 2022) |
| "5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) has activity in pancreatic neuroendocrine tumors (pNETs), but its use is limited, partly because of toxicities." | 8.02 | Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. ( Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J, 2021) |
| "The combination chemotherapy regimen capecitabine/temozolomide (CAPTEM) is efficacious for metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs), but its role in the neoadjuvant setting has not been established." | 7.96 | Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors. ( Abdel-Misih, S; Cloyd, JM; Dillhoff, ME; Dua, M; Konda, B; Norton, JA; Pawlik, TM; Poultsides, G; Schmidt, CR; Shah, MH; Squires, MH; Visser, BC; Worth, PJ, 2020) |
| "Although chemotherapy combining 5-fluorouracil (5FU)-dacarbazine (DTIC) or temozolomide (TEM)-capecitabine (CAP) is extensively used in patients with neuroendocrine tumors (NET), they were never compared." | 7.91 | Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. ( Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T, 2019) |
| "Both capecitabine alone and capecitabine in combination with temozolomide have activities against neuroendocrine tumors (NETs)." | 7.88 | Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. ( Chi, Y; Zhao, H; Zhao, J, 2018) |
| "An integrated protocol combining capecitibine-temozolomide with yttrium-90 radioembolization (CapTemY90) for liver-dominant grade 2 neuroendocrine tumors (NETs) was designed in the hope of achieving synergistic improvement in liver disease control with no more than additive toxicities." | 7.88 | Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors. ( Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D, 2018) |
| "Temozolomide (TMZ) is an alkylating agent frequently used in well-differentiated metastatic pancreatic neuroendocrine tumors (PNETs) with very variable responses." | 7.85 | Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. ( Caroli-Bosc, FX; Cauchin, E; Dumars, C; Foubert, F; Girot, P; Matysiak-Budnik, T; Mosnier, JF; Muzellec, L; Regenet, N; Senellart, H; Touchefeu, Y, 2017) |
| "Capecitabine and temozolomide chemotherapy was used in 65 patients with grade 1/2 neuroendocrine tumors (NETs)." | 7.85 | Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. ( Aller, J; Alonso, V; Alonso-Gordoa, T; Barriuso, J; Capdevila, J; Carmona-Bayonas, A; Crespo, G; Custodio, A; Gajate, P; Grande, E; Jiménez-Fonseca, P; López, C; Matos, I; Navarro, M; Nieto, B; Sevilla, I, 2017) |
| "The capecitabine and temozolomide (CAPTEM) regimen is active in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs), with response rates ranging from 30 to 70%." | 7.83 | Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. ( Black, M; Brelsford, M; Cives, M; Ghayouri, M; Meeker, A; Morse, B; Rizzo, A; Strosberg, J, 2016) |
| "Temozolomide (TEM) showed encouraging results in well-differentiated pancreatic neuroendocrine tumors (WDPNETs)." | 7.83 | MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. ( Bedossa, P; Couvelard, A; Cros, J; Gille, N; Hammel, P; Hentic, O; Lévy, P; Maire, F; Paradis, V; Rebours, V; Ruszniewski, P; Theou-Anton, N; Vernerey, D; Zappa, M, 2016) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 7.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "The authors retrospectively evaluated 3 patients with progressive, metastatic neuroendocrine tumors of the thymus who were treated with a combination of capecitabine and temozolomide." | 7.79 | Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series. ( Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J, 2013) |
| "Recent studies suggest that temozolomide has activity in neuroendocrine tumors." | 7.75 | O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Frauenhoffer, C; Fuchs, CS; Hooshmand, S; Hornick, JL; Kulke, MH; Meyerhardt, JA; Redston, MS; Ryan, DP; Stuart, K, 2009) |
| "Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia." | 7.74 | Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007) |
| "Temozolomide as monotherapy had acceptable toxicity and antitumoral effects in a small series of patients with advanced malignant neuroendocrine tumors and four of these showed radiologic responses." | 7.74 | Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. ( Dunder, K; Ekeblad, S; Eriksson, B; Granberg, D; Janson, ET; Kindmark, H; Kozlovacki, G; Oberg, K; Orlefors, H; Sigurd, M; Skogseid, B; Sundin, A; Welin, S, 2007) |
| "Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking." | 5.69 | Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. ( Amoroso, V; Berruti, A; Brizzi, MP; Colao, A; Faggiano, A; Fazio, N; Ferolla, P; Ghizzoni, S; Giuffrida, D; Houchard, A; Ibrahim, T; La Salvia, A; Marconcini, R; Mazzanti, P; Spada, F; Vaccaro, V; Volante, M, 2023) |
| "Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease." | 5.40 | Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. ( Abbasi, S; Albaba, H; Kashashna, A, 2014) |
| "The aim of the present study was to assess the effect of Endostar and temozolomide or dacarbazine plus 5-fluorouracil (5-FU) in patients with advanced pancreatic neuroendocrine tumors (pNETs)." | 5.27 | Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors. ( Bai, CM; Cheng, YJ; Gao, X; Meng, CT; Yan, XY; Ying, HY; Zhou, JF; Zhou, N, 2018) |
| "Abstract We conducted a phase I-II clinical trial to assess the safety and efficacy of combining lutetium-177 ((177)Lu)-octreotate with capecitabine and temozolomide in treating advanced low-grade neuroendocrine tumors (NETs)." | 5.16 | Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. ( Claringbold, PG; Price, RA; Turner, JH, 2012) |
| "Orally administered temozolomide and thalidomide seems to be an active regimen for the treatment of neuroendocrine tumors." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "Temozolomide (TEM) is an active treatment in metastatic neuroendocrine tumors (NETs)." | 5.12 | Should temozolomide be used on the basis of O ( Bagnardi, V; Curigliano, G; Fazio, N; Fumagalli, C; Gervaso, L; Guerini Rocco, E; Laffi, A; Peveri, G; Pisa, E; Rubino, M; Spada, F; Trillo Aliaga, P, 2021) |
| "Temozolomide (TEM) as a single agent or in combination with capecitabine (CAPTEM) is active in well-differentiated advanced neuroendocrine tumors (NETs) of gastro-entero-pancreatic and thoracic origin." | 4.31 | Prospective Evaluation of ( Andrini, E; Brighi, N; Campana, D; Donati, G; Lamberti, G; Lisotti, A; Manuzzi, L; Mosconi, C, 2023) |
| "The combination of capecitabine and temozolomide (CAPTEM) is one of the treatment options for metastatic pancreatic neuroendocrine neoplasms (pNENs)." | 4.12 | Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience. ( Chun, JW; Douangprachanh, S; Han, N; Han, SS; Jang, HY; Joo, HJ; Kim, TH; Koh, YH; Lee, WJ; Park, HM; Park, SJ; Woo, SM, 2022) |
| "The role of alternate sequential administration of sunitinib and capecitabine/temozolomide (CAPTEM) in metastatic pancreatic neuroendocrine tumors (PanNETs) remains unexplored." | 4.12 | Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors. ( Dong, J; Gao, H; Li, H; Liu, L; Ni, Q; Wang, W; Xu, H; Ye, L; Zhang, W, 2022) |
| "We evaluated outcomes of treatment with 5-fluorouracil (5-FU), doxorubicin, and streptozocin (FAS) in well-differentiated pancreatic neuroendocrine tumors (PanNETs) and its impact on subsequent therapy (everolimus or temozolomide)." | 4.12 | Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. ( Dagohoy, CG; Dasari, A; Halperin, DM; Lam, M; Rogers, JE; Yao, JC, 2022) |
| "The capecitabine/temozolomide (CAPTEM) regimen has significant activity in advanced neuroendocrine tumors (NETs)." | 4.02 | Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms. ( Al-Toubah, T; Haider, M; Pelle, E; Strosberg, JR; Valone, T, 2021) |
| "5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) has activity in pancreatic neuroendocrine tumors (pNETs), but its use is limited, partly because of toxicities." | 4.02 | Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. ( Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J, 2021) |
| "The combination of capecitabine (CAP) with temozolomide (TEM) chemotherapy in advanced pancreatic neuroendocrine tumors (PanNET) relies on limited evidence." | 3.96 | Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor. ( Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T, 2020) |
| " The capecitabine and temozolomide regimen has previously shown significant activity in patients with pancreatic neuroendocrine tumors (NETs) but has not been explored in metastatic lung NETs." | 3.96 | Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms. ( Al-Toubah, T; Morse, B; Strosberg, J, 2020) |
| "The combination chemotherapy regimen capecitabine/temozolomide (CAPTEM) is efficacious for metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs), but its role in the neoadjuvant setting has not been established." | 3.96 | Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors. ( Abdel-Misih, S; Cloyd, JM; Dillhoff, ME; Dua, M; Konda, B; Norton, JA; Pawlik, TM; Poultsides, G; Schmidt, CR; Shah, MH; Squires, MH; Visser, BC; Worth, PJ, 2020) |
| "Although chemotherapy combining 5-fluorouracil (5FU)-dacarbazine (DTIC) or temozolomide (TEM)-capecitabine (CAP) is extensively used in patients with neuroendocrine tumors (NET), they were never compared." | 3.91 | Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. ( Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T, 2019) |
| " Temozolomide (TMZ) has been proposed in patients with aggressive pituitary neuroendocrine tumors (PitNETs) who do not respond to conventional treatments." | 3.91 | Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. ( Albiger, N; Ceccato, F; Lombardi, G; Mazzai, L; Pambuku, A; Rolma, G; Scaroni, C; Zagonel, V, 2019) |
| "An integrated protocol combining capecitibine-temozolomide with yttrium-90 radioembolization (CapTemY90) for liver-dominant grade 2 neuroendocrine tumors (NETs) was designed in the hope of achieving synergistic improvement in liver disease control with no more than additive toxicities." | 3.88 | Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors. ( Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D, 2018) |
| "Both capecitabine alone and capecitabine in combination with temozolomide have activities against neuroendocrine tumors (NETs)." | 3.88 | Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. ( Chi, Y; Zhao, H; Zhao, J, 2018) |
| "Capecitabine and temozolomide chemotherapy was used in 65 patients with grade 1/2 neuroendocrine tumors (NETs)." | 3.85 | Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. ( Aller, J; Alonso, V; Alonso-Gordoa, T; Barriuso, J; Capdevila, J; Carmona-Bayonas, A; Crespo, G; Custodio, A; Gajate, P; Grande, E; Jiménez-Fonseca, P; López, C; Matos, I; Navarro, M; Nieto, B; Sevilla, I, 2017) |
| "Temozolomide (TMZ) is an alkylating agent frequently used in well-differentiated metastatic pancreatic neuroendocrine tumors (PNETs) with very variable responses." | 3.85 | Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. ( Caroli-Bosc, FX; Cauchin, E; Dumars, C; Foubert, F; Girot, P; Matysiak-Budnik, T; Mosnier, JF; Muzellec, L; Regenet, N; Senellart, H; Touchefeu, Y, 2017) |
| "Temozolomide (TEM) showed encouraging results in well-differentiated pancreatic neuroendocrine tumors (WDPNETs)." | 3.83 | MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. ( Bedossa, P; Couvelard, A; Cros, J; Gille, N; Hammel, P; Hentic, O; Lévy, P; Maire, F; Paradis, V; Rebours, V; Ruszniewski, P; Theou-Anton, N; Vernerey, D; Zappa, M, 2016) |
| "The capecitabine and temozolomide (CAPTEM) regimen is active in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs), with response rates ranging from 30 to 70%." | 3.83 | Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. ( Black, M; Brelsford, M; Cives, M; Ghayouri, M; Meeker, A; Morse, B; Rizzo, A; Strosberg, J, 2016) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 3.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "The authors retrospectively evaluated 3 patients with progressive, metastatic neuroendocrine tumors of the thymus who were treated with a combination of capecitabine and temozolomide." | 3.79 | Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series. ( Centeno, B; Kvols, L; Morse, B; Saranga-Perry, V; Strosberg, J, 2013) |
| "We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver." | 3.79 | Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. ( Allendorf, J; Chabot, JA; Dinnen, RD; Fine, RL; Gulati, AP; Krantz, BA; Lee, JA; Mao, Y; Moss, RA; Mowatt, KB; Schreibman, S; Schrope, B; Sherman, WH; Stevens, PD; Tsushima, DA, 2013) |
| "Recent studies suggest that temozolomide has activity in neuroendocrine tumors." | 3.75 | O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Frauenhoffer, C; Fuchs, CS; Hooshmand, S; Hornick, JL; Kulke, MH; Meyerhardt, JA; Redston, MS; Ryan, DP; Stuart, K, 2009) |
| "Temozolomide as monotherapy had acceptable toxicity and antitumoral effects in a small series of patients with advanced malignant neuroendocrine tumors and four of these showed radiologic responses." | 3.74 | Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. ( Dunder, K; Ekeblad, S; Eriksson, B; Granberg, D; Janson, ET; Kindmark, H; Kozlovacki, G; Oberg, K; Orlefors, H; Sigurd, M; Skogseid, B; Sundin, A; Welin, S, 2007) |
| "Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia." | 3.74 | Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007) |
| "Bronchial carcinoids are uncommon tumors accounting for 20 to 30% of all neuroendocrine tumors and about 1-2% of all cancers of pulmonary origin." | 2.66 | Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. ( Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D, 2020) |
| "CAPTEM is effective and relatively safe for treating patients with advanced NENs." | 2.58 | Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis. ( Fu, W; Li, W; Lu, L; Lu, Y; Lv, W; Wang, J; Zhao, Z, 2018) |
| " Commenced 15 years ago, PRRT is now becoming established as first- and second-line therapy for gastroentero pancreatic neuroendocrine tumors (GEPNETs), and early treatment minimizes myelotoxicity, which is the most significant potential adverse event following PRRT." | 2.53 | Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. ( Kesavan, M; Turner, JH, 2016) |
| "Temozolomide (TMZ) is an oral, potentially less toxic derivative of dacarbazine, which has shown activity both as a single agent and in combination with other drugs." | 2.52 | Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. ( Barberis, M; Berruti, A; Fazio, N; Fumagalli, C; Galdy, S; Kaltsas, G; Koumarianou, A; Kulke, MH; Oberg, K; Spada, F; Strosberg, JR, 2015) |
| "Advanced neuroendocrine tumors are incurable, and most patients will succumb to the disease." | 2.52 | Cytotoxic chemotherapy for pancreatic neuroendocrine tumors. ( Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Takahashi, H; Ueno, H, 2015) |
| "Later, TMZ proved its efficacy in the treatment of melanoma." | 2.49 | Temozolomide and unusual indications: review of literature. ( Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E, 2013) |
| "The majority of anterior pituitary tumors behave benignly, that is, they grow slowly and do not metastasize, and were therefore called adenomas." | 1.91 | Aggressive pituitary tumors (PitNETs). ( Nishioka, H, 2023) |
| "Pre-temozolomide treatment, these data were 5." | 1.91 | Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain. ( Araujo-Castro, M; Biagetti, B; Cámara, R; Fajardo, C; García-Centeno, R; Guerrero-Pérez, F; Hanzu, F; Iglesias, P; Lamas, C; Mora, M; Remon-Ruiz, P; Soto, A, 2023) |
| "Patients received oral TEM alone or in combination with CAP." | 1.62 | Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. ( Antonuzzo, L; Barberis, M; Campana, D; Faviana, P; Fazio, N; Fumagalli, C; Gelsomino, F; Maisonneuve, P; Marconcini, R; Messerini, L; Puliafito, I; Rossi, G; Spada, F, 2021) |
| "CAPTEM treatment can be an effective and safe treatment even after prolonged administration for patients with NENs of various sites and Ki67 labeling index, associated with significant favorable responses and PFS." | 1.51 | Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms. ( Alexandraki, KI; Angelousi, A; Chatzellis, E; Daskalakis, K; Gross, D; Grozinsky-Glasberg, S; Kaltsas, G; Kos-Kudła, B; Koumarianou, A; Maimon, O; Meirovitz, A; Tsoli, M; Wachuła, E, 2019) |
| "Neuroendocrine tumors are rare, and little is known about the existence of cancer stem cells in this disease." | 1.46 | Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor. ( Asai, A; Ito, T; Iwata, R; Kanemura, Y; Koike, T; Maruyama, M; Nakano, Y; Nomura, S; Nonaka, M; Oe, S; Sugimoto, T; Yamada, H; Yoshimura, K, 2017) |
| "Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease." | 1.40 | Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. ( Abbasi, S; Albaba, H; Kashashna, A, 2014) |
| "Temozolomide monotherapy has limited effect in treatment of recurrent neuroendocrine carcinomas." | 1.38 | Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ( Federspiel, B; Hansen, CP; Kjaer, A; Knigge, U; Langer, SW; Olsen, IH; Sørensen, JB, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (6.38) | 29.6817 |
| 2010's | 51 (54.26) | 24.3611 |
| 2020's | 37 (39.36) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Toubah, T | 4 |
| Morse, B | 5 |
| Strosberg, J | 5 |
| Gao, H | 2 |
| Dong, J | 2 |
| Zhang, W | 2 |
| Xu, H | 2 |
| Ye, L | 2 |
| Li, H | 2 |
| Wang, W | 3 |
| Liu, L | 2 |
| Yu, X | 1 |
| Hiddinga, B | 1 |
| Zwaenepoel, K | 1 |
| Janssens, A | 2 |
| Van Meerbeeck, J | 1 |
| Pauwels, P | 2 |
| Ferolla, P | 2 |
| Berruti, A | 3 |
| Spada, F | 5 |
| Brizzi, MP | 2 |
| Ibrahim, T | 2 |
| Marconcini, R | 2 |
| Giuffrida, D | 1 |
| Amoroso, V | 2 |
| La Salvia, A | 2 |
| Vaccaro, V | 1 |
| Faggiano, A | 2 |
| Colao, A | 2 |
| Volante, M | 1 |
| Ghizzoni, S | 1 |
| Mazzanti, P | 1 |
| Houchard, A | 1 |
| Fazio, N | 5 |
| Dogan, I | 1 |
| Tastekin, D | 2 |
| Karabulut, S | 2 |
| Sakar, B | 1 |
| Owen, DH | 1 |
| Benner, B | 1 |
| Wei, L | 1 |
| Sukrithan, V | 1 |
| Goyal, A | 1 |
| Zhou, Y | 1 |
| Pilcher, C | 1 |
| Suffren, SA | 1 |
| Christenson, G | 1 |
| Curtis, N | 1 |
| Jukich, M | 1 |
| Schwarz, E | 1 |
| Savardekar, H | 1 |
| Norman, R | 1 |
| Ferguson, S | 1 |
| Kleiber, B | 1 |
| Wesolowski, R | 1 |
| Carson, WE | 1 |
| Otterson, GA | 1 |
| Verschraegen, CF | 1 |
| Shah, MH | 2 |
| Konda, B | 2 |
| Douangprachanh, S | 1 |
| Joo, HJ | 1 |
| Park, HM | 1 |
| Han, N | 1 |
| Jang, HY | 1 |
| Koh, YH | 1 |
| Kim, TH | 1 |
| Han, SS | 1 |
| Park, SJ | 1 |
| Lee, WJ | 1 |
| Woo, SM | 1 |
| Chun, JW | 1 |
| Boutin, M | 3 |
| Mathews, A | 3 |
| Badesha, J | 3 |
| Paul, A | 3 |
| Safro, M | 3 |
| Gill, S | 3 |
| Stuart, HC | 3 |
| Schaeffer, D | 3 |
| Farnell, D | 3 |
| Loree, JM | 3 |
| Velez, MA | 2 |
| Garon, EB | 2 |
| Brighi, N | 2 |
| Lamberti, G | 1 |
| Andrini, E | 1 |
| Mosconi, C | 1 |
| Manuzzi, L | 1 |
| Donati, G | 1 |
| Lisotti, A | 1 |
| Campana, D | 3 |
| Nishioka, H | 1 |
| Navale, P | 1 |
| Chatterjee, D | 1 |
| Itani, M | 1 |
| Trikalinos, NA | 1 |
| Ünal, Ç | 1 |
| Azizy, A | 1 |
| Akyıldız, A | 1 |
| Yaşar, S | 1 |
| Yalçın, Ş | 1 |
| Çoban, E | 1 |
| Evrensel, T | 1 |
| Kalkan, Z | 1 |
| Oruç, Z | 1 |
| Derin, S | 1 |
| Turna, ZH | 1 |
| Bayram, D | 1 |
| Köş, FT | 1 |
| Şendur, MAN | 1 |
| Sever, N | 1 |
| Ercelep, Ö | 1 |
| Seyyar, M | 1 |
| Kefeli, U | 1 |
| Uygun, K | 1 |
| Özçelik, M | 1 |
| Ön, S | 1 |
| Şanlı, UA | 1 |
| Canaslan, K | 1 |
| Ünek, İT | 1 |
| Yücel, KB | 1 |
| Özdemir, N | 1 |
| Yazıcı, O | 1 |
| Güzel, HG | 1 |
| Salim, DK | 1 |
| Göksu, SS | 1 |
| Tatlı, AM | 1 |
| Ordu, Ç | 1 |
| Selvi, O | 1 |
| Sakin, A | 1 |
| Büyükbayram, ME | 1 |
| Dursun, B | 1 |
| Ürün, Y | 1 |
| Arak, H | 1 |
| Ağdaş, G | 1 |
| Uğraklı, M | 1 |
| Hendem, E | 1 |
| Eryılmaz, MK | 1 |
| Bilgin, B | 1 |
| Topçu, A | 1 |
| Şimşek, M | 1 |
| Büyükşimşek, M | 1 |
| Akay, B | 1 |
| Erdal, GŞ | 1 |
| Karataş, F | 1 |
| Alan, Ö | 1 |
| Çağlayan, M | 1 |
| Kahvecioğlu, FA | 1 |
| Demirci, A | 1 |
| Paksoy, N | 1 |
| Çetin, B | 1 |
| Gümüş, M | 1 |
| Ak, N | 1 |
| Aydınalp, Y | 1 |
| Paydaş, S | 1 |
| Güven, DC | 1 |
| Kılıçkap, S | 1 |
| Sağlam, S | 1 |
| Ørting, AM | 1 |
| Clausen, MM | 1 |
| Soldath, P | 1 |
| Petersen, RH | 1 |
| Knigge, U | 2 |
| Andreassen, M | 1 |
| Kjær, A | 1 |
| Langer, SW | 2 |
| Lamas, C | 1 |
| Cámara, R | 1 |
| Fajardo, C | 1 |
| Remon-Ruiz, P | 1 |
| Biagetti, B | 1 |
| Guerrero-Pérez, F | 1 |
| Araujo-Castro, M | 1 |
| Mora, M | 1 |
| Hanzu, F | 1 |
| Iglesias, P | 1 |
| García-Centeno, R | 1 |
| Soto, A | 1 |
| Papaxoinis, G | 1 |
| Kordatou, Z | 1 |
| McCallum, L | 1 |
| Nasralla, M | 1 |
| Lamarca, A | 3 |
| Backen, A | 2 |
| Nonaka, D | 1 |
| Mansoor, W | 2 |
| Barriuso, J | 3 |
| McNamara, MG | 2 |
| Hubner, RA | 1 |
| Manoharan, P | 1 |
| Valle, JW | 2 |
| Chatzellis, E | 2 |
| Daskalakis, K | 2 |
| Angelousi, A | 2 |
| Tsoli, M | 2 |
| Alexandraki, KI | 2 |
| Wachula, E | 1 |
| Meirovitz, A | 2 |
| Maimon, O | 2 |
| Grozinsky-Glasberg, S | 2 |
| Gross, D | 2 |
| Kos-Kudła, B | 2 |
| Koumarianou, A | 4 |
| Kaltsas, G | 4 |
| Wu, YL | 1 |
| Raj, N | 2 |
| Reidy-Lagunes, D | 3 |
| Squires, MH | 1 |
| Worth, PJ | 1 |
| Dillhoff, ME | 1 |
| Abdel-Misih, S | 1 |
| Norton, JA | 1 |
| Visser, BC | 2 |
| Dua, M | 1 |
| Pawlik, TM | 1 |
| Schmidt, CR | 1 |
| Poultsides, G | 1 |
| Cloyd, JM | 1 |
| April-Monn, SL | 1 |
| Wiedmer, T | 1 |
| Skowronska, M | 1 |
| Maire, R | 1 |
| Schiavo Lena, M | 1 |
| Trippel, M | 1 |
| Di Domenico, A | 1 |
| Muffatti, F | 1 |
| Andreasi, V | 1 |
| Capurso, G | 1 |
| Doglioni, C | 1 |
| Kim-Fuchs, C | 1 |
| Gloor, B | 1 |
| Zatelli, MC | 1 |
| Partelli, S | 1 |
| Falconi, M | 1 |
| Perren, A | 2 |
| Marinoni, I | 1 |
| Bergquist, JR | 1 |
| Li, AY | 1 |
| Chang, EM | 1 |
| Scott, GD | 1 |
| Dua, MM | 1 |
| Zhang, Y | 2 |
| Peng, Y | 1 |
| Jin, KZ | 1 |
| Li, YL | 1 |
| Liang, Y | 1 |
| Tan, HY | 1 |
| Yu, XJ | 1 |
| Zhou, ZW | 1 |
| Chen, J | 1 |
| Maisonneuve, P | 2 |
| Fumagalli, C | 3 |
| Gelsomino, F | 2 |
| Antonuzzo, L | 1 |
| Puliafito, I | 1 |
| Rossi, G | 1 |
| Faviana, P | 1 |
| Messerini, L | 1 |
| Barberis, M | 2 |
| Uprety, D | 1 |
| Halfdanarson, TR | 1 |
| Molina, JR | 1 |
| Leventakos, K | 1 |
| Ostwal, V | 1 |
| Basu, S | 1 |
| Bhargava, P | 2 |
| Shah, M | 1 |
| Parghane, RV | 1 |
| Srinivas, S | 1 |
| Chaudhari, V | 1 |
| Bhandare, MS | 1 |
| Shrikhande, SV | 1 |
| Ramaswamy, A | 1 |
| Bongiovanni, A | 1 |
| Liverani, C | 1 |
| Foca, F | 1 |
| Fausti, V | 1 |
| Di Menna, G | 1 |
| Mercatali, L | 1 |
| De Vita, A | 1 |
| Riva, N | 1 |
| Calpona, S | 1 |
| Miserocchi, G | 1 |
| Spadazzi, C | 1 |
| Cocchi, C | 1 |
| Pelle, E | 2 |
| Rogers, JE | 1 |
| Lam, M | 1 |
| Halperin, DM | 1 |
| Dagohoy, CG | 1 |
| Yao, JC | 1 |
| Dasari, A | 1 |
| Kesavan, M | 3 |
| Grover, P | 1 |
| Lam, WS | 1 |
| Claringbold, PG | 4 |
| Turner, JH | 5 |
| Smit, AM | 1 |
| Kilian, S | 1 |
| Emsley, RA | 1 |
| Luckhoff, HK | 1 |
| Swartz, L | 1 |
| Seedat, S | 1 |
| Asmal, L | 1 |
| Kloppers, JF | 1 |
| de Kock, A | 1 |
| Cronjé, J | 1 |
| van Marle, AC | 1 |
| Aouad, MR | 1 |
| Khan, DJO | 1 |
| Said, MA | 1 |
| Al-Kaff, NS | 1 |
| Rezki, N | 1 |
| Ali, AA | 1 |
| Bouqellah, N | 1 |
| Hagar, M | 1 |
| Sanga, G | 1 |
| Jao, I | 1 |
| Mumba, N | 1 |
| Mwalukore, S | 1 |
| Kamuya, D | 1 |
| Davies, A | 1 |
| McGready, R | 1 |
| Rijken, MJ | 1 |
| Turner, C | 1 |
| Than, HH | 1 |
| Tun, NW | 1 |
| Min, AM | 1 |
| Hla, S | 1 |
| Wai, NS | 1 |
| Proux, K | 1 |
| Min, TH | 1 |
| Gilder, ME | 1 |
| Sneddon, A | 1 |
| Sorbera, M | 1 |
| Fischetti, B | 1 |
| Khaimova, R | 1 |
| Niewinski, M | 1 |
| Wen, K | 1 |
| Tarke, A | 1 |
| Sidney, J | 1 |
| Methot, N | 1 |
| Yu, ED | 1 |
| Dan, JM | 1 |
| Goodwin, B | 1 |
| Rubiro, P | 1 |
| Sutherland, A | 1 |
| Wang, E | 1 |
| Frazier, A | 1 |
| Ramirez, SI | 1 |
| Rawlings, SA | 1 |
| Smith, DM | 1 |
| da Silva Antunes, R | 1 |
| Peters, B | 1 |
| Scheuermann, RH | 1 |
| Weiskopf, D | 1 |
| Crotty, S | 1 |
| Grifoni, A | 1 |
| Sette, A | 1 |
| Yan, P | 1 |
| Liang, DY | 1 |
| Xu, WH | 1 |
| Xue, L | 1 |
| Yu, MF | 1 |
| Shen, JH | 1 |
| Liu, QH | 1 |
| Peng, YB | 1 |
| Arenas, M | 1 |
| Algara, M | 1 |
| De Febrer, G | 1 |
| Rubio, C | 1 |
| Sanz, X | 1 |
| de la Casa, MA | 1 |
| Vasco, C | 1 |
| Marín, J | 1 |
| Fernández-Letón, P | 1 |
| Villar, J | 1 |
| Torres-Royo, L | 1 |
| Villares, P | 1 |
| Membrive, I | 1 |
| Acosta, J | 1 |
| López-Cano, M | 1 |
| Araguas, P | 1 |
| Quera, J | 1 |
| Rodríguez-Tomás, F | 1 |
| Montero, A | 1 |
| Buchler, A | 1 |
| Munch, M | 1 |
| Farber, G | 1 |
| Zhao, X | 1 |
| Al-Haddad, R | 1 |
| Farber, E | 1 |
| Rotstein, BH | 1 |
| Hou, J | 1 |
| Long, T | 1 |
| Yang, N | 1 |
| Chen, D | 1 |
| Zeng, S | 1 |
| Zheng, K | 1 |
| Liao, G | 1 |
| Hu, S | 1 |
| De Gregori, S | 1 |
| De Silvestri, A | 1 |
| Molinaro, MD | 1 |
| Monzillo, V | 1 |
| Biscarini, S | 1 |
| Colaneri, M | 1 |
| Gallazzi, I | 1 |
| Bartoli, A | 1 |
| Bruno, R | 1 |
| Seminari, E | 1 |
| Dang, W | 1 |
| Xiao, J | 1 |
| Ma, Q | 1 |
| Miao, J | 1 |
| Cao, M | 1 |
| Chen, L | 1 |
| Shi, Y | 1 |
| Yao, X | 1 |
| Yu, S | 1 |
| Liu, X | 2 |
| Cui, Y | 1 |
| Zhang, X | 1 |
| Bian, X | 1 |
| Norlin, JM | 1 |
| Kellerborg, K | 1 |
| Odin, P | 1 |
| Trillo Aliaga, P | 1 |
| Peveri, G | 1 |
| Bagnardi, V | 1 |
| Laffi, A | 2 |
| Rubino, M | 2 |
| Gervaso, L | 1 |
| Guerini Rocco, E | 1 |
| Pisa, E | 1 |
| Curigliano, G | 1 |
| Lania, A | 1 |
| Ferraù, F | 1 |
| Modica, R | 1 |
| Valone, T | 1 |
| Haider, M | 1 |
| Strosberg, JR | 2 |
| Ni, Q | 1 |
| Girot, P | 1 |
| Dumars, C | 1 |
| Mosnier, JF | 1 |
| Muzellec, L | 1 |
| Senellart, H | 1 |
| Foubert, F | 1 |
| Caroli-Bosc, FX | 1 |
| Cauchin, E | 1 |
| Regenet, N | 1 |
| Matysiak-Budnik, T | 1 |
| Touchefeu, Y | 1 |
| Iwata, R | 1 |
| Maruyama, M | 1 |
| Ito, T | 2 |
| Nakano, Y | 1 |
| Kanemura, Y | 1 |
| Koike, T | 1 |
| Oe, S | 1 |
| Yoshimura, K | 1 |
| Nonaka, M | 1 |
| Nomura, S | 1 |
| Sugimoto, T | 1 |
| Yamada, H | 1 |
| Asai, A | 1 |
| Klimstra, DS | 1 |
| Horvat, N | 1 |
| Zhang, L | 1 |
| Chou, JF | 1 |
| Capanu, M | 1 |
| Basturk, O | 1 |
| Do, RKG | 1 |
| Allen, PJ | 1 |
| Zhao, J | 1 |
| Zhao, H | 1 |
| Chi, Y | 1 |
| Walter, T | 4 |
| Pusceddu, S | 1 |
| Graillot, E | 1 |
| Prinzi, N | 1 |
| Spallanzani, A | 1 |
| Fiorentino, M | 1 |
| Barritault, M | 2 |
| Dall'Olio, F | 1 |
| Biasco, G | 1 |
| Thakral, P | 1 |
| Sen, I | 1 |
| Pant, V | 1 |
| Gupta, SK | 1 |
| Dureja, S | 1 |
| Kumari, J | 1 |
| Kumar, S | 1 |
| Un, P | 1 |
| Malasani, V | 1 |
| Soulen, MC | 1 |
| van Houten, D | 1 |
| Teitelbaum, UR | 1 |
| Damjanov, N | 1 |
| Cengel, KA | 1 |
| Metz, DC | 1 |
| Lu, Y | 1 |
| Zhao, Z | 1 |
| Wang, J | 1 |
| Lv, W | 1 |
| Lu, L | 1 |
| Fu, W | 1 |
| Li, W | 1 |
| Pozzari, M | 1 |
| Cella, CA | 1 |
| Pellicori, S | 1 |
| Bertani, E | 1 |
| Muratori, L | 1 |
| Trevisi, E | 1 |
| Di Maio, M | 1 |
| Scagliotti, GV | 1 |
| Cheng, YJ | 1 |
| Meng, CT | 1 |
| Ying, HY | 1 |
| Zhou, JF | 1 |
| Yan, XY | 1 |
| Gao, X | 1 |
| Zhou, N | 1 |
| Bai, CM | 1 |
| de Mestier, L | 2 |
| Brixi, H | 1 |
| Evrard, C | 2 |
| Legoux, JL | 1 |
| de Boissieu, P | 2 |
| Hentic, O | 4 |
| Cros, J | 4 |
| Hammel, P | 4 |
| Tougeron, D | 2 |
| Lombard-Bohas, C | 3 |
| Rebours, V | 3 |
| Ruszniewski, P | 4 |
| Cadiot, G | 1 |
| Lemelin, A | 1 |
| Hervieu, V | 1 |
| Payen, L | 1 |
| Péron, J | 1 |
| Couvelard, A | 2 |
| Scoazec, JY | 1 |
| Bin, S | 1 |
| Villeneuve, L | 1 |
| Yordanova, A | 1 |
| Ahrens, H | 1 |
| Feldmann, G | 1 |
| Brossart, P | 1 |
| Gaertner, FC | 1 |
| Fottner, C | 1 |
| Weber, MM | 1 |
| Ahmadzadehfar, H | 1 |
| Schreckenberger, M | 1 |
| Miederer, M | 1 |
| Essler, M | 1 |
| Ceccato, F | 1 |
| Lombardi, G | 1 |
| Albiger, N | 1 |
| Mazzai, L | 1 |
| Pambuku, A | 1 |
| Rolma, G | 1 |
| Zagonel, V | 1 |
| Scaroni, C | 1 |
| Joseph, R | 1 |
| McRee, AJ | 1 |
| Mathews, S | 1 |
| Zeidner, JF | 1 |
| Wachuła, E | 1 |
| Costa, FP | 1 |
| Gumz, B | 1 |
| Pasche, B | 1 |
| Chan, JA | 2 |
| Blaszkowsky, L | 2 |
| Stuart, K | 4 |
| Zhu, AX | 1 |
| Allen, J | 1 |
| Wadlow, R | 1 |
| Ryan, DP | 3 |
| Meyerhardt, J | 1 |
| Gonzalez, M | 1 |
| Regan, E | 1 |
| Zheng, H | 2 |
| Kulke, MH | 7 |
| Saif, MW | 2 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Rodriguez, T | 1 |
| Tejani, MA | 1 |
| Schmitt, AM | 1 |
| Pavel, M | 1 |
| Rudolph, T | 1 |
| Dawson, H | 1 |
| Blank, A | 1 |
| Komminoth, P | 1 |
| Vassella, E | 1 |
| Abbasi, S | 1 |
| Kashashna, A | 1 |
| Albaba, H | 1 |
| Rashidi, A | 1 |
| Sorscher, SM | 1 |
| Abdel-Rahman, O | 1 |
| Fouad, M | 1 |
| Oberg, K | 2 |
| Galdy, S | 1 |
| Okusaka, T | 1 |
| Ueno, H | 1 |
| Morizane, C | 1 |
| Kondo, S | 1 |
| Sakamoto, Y | 1 |
| Takahashi, H | 1 |
| Ohno, I | 1 |
| Shimizu, S | 1 |
| Mitsunaga, S | 1 |
| Ikeda, M | 1 |
| Elliott, E | 1 |
| Hubner, R | 1 |
| Kamiya-Matsuoka, C | 1 |
| Cachia, D | 1 |
| Waguespack, SG | 1 |
| Crane, CH | 1 |
| Mahajan, A | 1 |
| Brown, PD | 1 |
| Nam, JY | 1 |
| McCutcheon, IE | 1 |
| Penas-Prado, M | 1 |
| Ramirez, RA | 1 |
| Beyer, DT | 1 |
| Chauhan, A | 1 |
| Boudreaux, JP | 1 |
| Wang, YZ | 1 |
| Woltering, EA | 1 |
| Zappa, M | 1 |
| Gille, N | 1 |
| Theou-Anton, N | 1 |
| Vernerey, D | 1 |
| Maire, F | 1 |
| Lévy, P | 1 |
| Bedossa, P | 1 |
| Paradis, V | 1 |
| Hiddinga, BI | 1 |
| van Meerbeeck, JP | 1 |
| Cives, M | 1 |
| Ghayouri, M | 1 |
| Brelsford, M | 1 |
| Black, M | 1 |
| Rizzo, A | 1 |
| Meeker, A | 1 |
| Crespo, G | 1 |
| Jiménez-Fonseca, P | 1 |
| Custodio, A | 1 |
| López, C | 1 |
| Carmona-Bayonas, A | 1 |
| Alonso, V | 1 |
| Navarro, M | 1 |
| Aller, J | 1 |
| Sevilla, I | 1 |
| Grande, E | 1 |
| Gajate, P | 1 |
| Alonso-Gordoa, T | 1 |
| Matos, I | 1 |
| Capdevila, J | 1 |
| Nieto, B | 1 |
| Wang, L | 1 |
| Matkar, S | 1 |
| Xie, G | 1 |
| An, C | 1 |
| He, X | 1 |
| Kong, X | 1 |
| Hua, X | 1 |
| Bracht, LK | 1 |
| Wen, P | 1 |
| Meyerhardt, JA | 3 |
| Hornick, JL | 2 |
| Redston, M | 1 |
| LaFrankie, DC | 1 |
| Black, PM | 1 |
| Kesari, S | 1 |
| Norden, A | 1 |
| Drappatz, J | 1 |
| Frauenhoffer, C | 1 |
| Hooshmand, S | 1 |
| Enzinger, PC | 3 |
| Clark, JW | 3 |
| Fuchs, CS | 3 |
| Redston, MS | 1 |
| Eriksson, B | 2 |
| Antoniou, S | 1 |
| Kanakis, G | 1 |
| Economopoulos, N | 1 |
| Rontogianni, D | 1 |
| Ntavatzikos, A | 1 |
| Tsavaris, N | 1 |
| Pectasides, D | 1 |
| Dimitriadis, G | 1 |
| Thornton, R | 1 |
| Earle, CC | 1 |
| Miksad, R | 1 |
| Tatar, Z | 1 |
| Thivat, E | 1 |
| Planchat, E | 1 |
| Gimbergues, P | 1 |
| Gadea, E | 1 |
| Abrial, C | 1 |
| Durando, X | 1 |
| Neuzillet, C | 1 |
| Faivre, S | 2 |
| Raymond, E | 2 |
| Dreyer, C | 1 |
| Olsen, IH | 1 |
| Sørensen, JB | 1 |
| Federspiel, B | 1 |
| Kjaer, A | 1 |
| Hansen, CP | 1 |
| Igarashi, H | 1 |
| Jensen, RT | 1 |
| Takayanagi, R | 1 |
| Price, RA | 1 |
| Saranga-Perry, V | 1 |
| Centeno, B | 1 |
| Kvols, L | 1 |
| Fine, RL | 1 |
| Gulati, AP | 1 |
| Krantz, BA | 1 |
| Moss, RA | 1 |
| Schreibman, S | 1 |
| Tsushima, DA | 1 |
| Mowatt, KB | 1 |
| Dinnen, RD | 1 |
| Mao, Y | 1 |
| Stevens, PD | 1 |
| Schrope, B | 1 |
| Allendorf, J | 1 |
| Lee, JA | 1 |
| Sherman, WH | 1 |
| Chabot, JA | 1 |
| Muzikansky, A | 1 |
| Vincitore, M | 2 |
| Michelini, A | 2 |
| Kerr, C | 1 |
| Ekeblad, S | 1 |
| Sundin, A | 1 |
| Janson, ET | 1 |
| Welin, S | 1 |
| Granberg, D | 1 |
| Kindmark, H | 1 |
| Dunder, K | 1 |
| Kozlovacki, G | 1 |
| Orlefors, H | 1 |
| Sigurd, M | 1 |
| Skogseid, B | 1 |
| Schwarzberg, AB | 1 |
| Stover, EH | 1 |
| Sengupta, T | 1 |
| Baden, LR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents[NCT03217097] | 116 participants (Actual) | Interventional | 2018-10-16 | Completed | |||
| Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma[NCT05532397] | 10 participants (Anticipated) | Interventional | 2023-02-17 | Recruiting | |||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| An Italian Multicenter Phase II Trial of Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study[NCT05554003] | Phase 2 | 46 participants (Anticipated) | Interventional | 2022-01-14 | Recruiting | ||
| A Phase II Study of Bevacizumab in Combination With Temozolomide in Patients With Advanced Neuroendocrine Tumors[NCT00137774] | Phase 2 | 34 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for temozolomide and Neuroendocrine Tumors
| Article | Year |
|---|---|
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecita | 2020 |
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecita | 2020 |
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecita | 2020 |
Should temozolomide be used on the basis of O
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; DNA Modification | 2021 |
Should temozolomide be used on the basis of O
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; DNA Modification | 2021 |
Should temozolomide be used on the basis of O
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; DNA Modification | 2021 |
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neo | 2021 |
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neo | 2021 |
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neo | 2021 |
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Huma | 2018 |
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Huma | 2018 |
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Huma | 2018 |
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytoreduction Surgical Procedures; Hum | 2018 |
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytoreduction Surgical Procedures; Hum | 2018 |
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytoreduction Surgical Procedures; Hum | 2018 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell | 2012 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell | 2012 |
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell | 2012 |
Medical treatment of advanced thoracic neuroendocrine tumors.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Dacarbazine; Everolimus; Humans; Neuroendocrine | 2014 |
Medical treatment of advanced thoracic neuroendocrine tumors.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Dacarbazine; Everolimus; Humans; Neuroendocrine | 2014 |
Medical treatment of advanced thoracic neuroendocrine tumors.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Dacarbazine; Everolimus; Humans; Neuroendocrine | 2014 |
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Dacarbazine; Everolimus; | 2015 |
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Dacarbazine; Everolimus; | 2015 |
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Dacarbazine; Everolimus; | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine Tumors; Temozolomide | 2015 |
Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine | 2015 |
Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine | 2015 |
Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Neuroendocrine | 2015 |
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Di | 2016 |
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Di | 2016 |
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Di | 2016 |
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; N | 2016 |
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; N | 2016 |
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; N | 2016 |
O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; | 2017 |
O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; | 2017 |
O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; | 2017 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluoroura | 2010 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluoroura | 2010 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluoroura | 2010 |
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbaz | 2012 |
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbaz | 2012 |
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbaz | 2012 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
New treatment options with cytotoxic agents in neuroendocrine tumours.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Clinical Trials as | 2012 |
New treatment options with cytotoxic agents in neuroendocrine tumours.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Clinical Trials as | 2012 |
New treatment options with cytotoxic agents in neuroendocrine tumours.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Clinical Trials as | 2012 |
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immuno | 2012 |
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immuno | 2012 |
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immuno | 2012 |
12 trials available for temozolomide and Neuroendocrine Tumors
| Article | Year |
|---|---|
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
Topics: Carcinoid Tumor; Female; Humans; Male; Neuroendocrine Tumors; Pilot Projects; Prospective Studies; T | 2023 |
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
Topics: Carcinoid Tumor; Female; Humans; Male; Neuroendocrine Tumors; Pilot Projects; Prospective Studies; T | 2023 |
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
Topics: Carcinoid Tumor; Female; Humans; Male; Neuroendocrine Tumors; Pilot Projects; Prospective Studies; T | 2023 |
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; | 2021 |
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; | 2021 |
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies | 2021 |
Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; D | 2018 |
Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; D | 2018 |
Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; D | 2018 |
O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; DNA Methylation; | 2019 |
O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; DNA Methylation; | 2019 |
O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; DNA Methylation; | 2019 |
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dru | 2013 |
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dru | 2013 |
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dru | 2013 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidin | 2014 |
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Da | 2016 |
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Da | 2016 |
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Da | 2016 |
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; | 2012 |
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; | 2012 |
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; | 2012 |
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dru | 2012 |
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dru | 2012 |
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dru | 2012 |
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2012 |
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2012 |
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combin | 2012 |
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An | 2006 |
64 other studies available for temozolomide and Neuroendocrine Tumors
| Article | Year |
|---|---|
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Retrosp | 2022 |
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Retrosp | 2022 |
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Retrosp | 2022 |
The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Prospec | 2022 |
The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Prospec | 2022 |
The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs with or without maintenance therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neuroendocrine Tumors; Prospec | 2022 |
Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
Topics: Anaplastic Lymphoma Kinase; Biomarkers; Carcinoid Tumor; Carcinoma, Neuroendocrine; DNA; DNA Methyla | 2022 |
Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
Topics: Anaplastic Lymphoma Kinase; Biomarkers; Carcinoid Tumor; Carcinoma, Neuroendocrine; DNA; DNA Methyla | 2022 |
Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
Topics: Anaplastic Lymphoma Kinase; Biomarkers; Carcinoid Tumor; Carcinoma, Neuroendocrine; DNA; DNA Methyla | 2022 |
Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female | 2022 |
Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female | 2022 |
Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female | 2022 |
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Topics: Humans; Lung Neoplasms; Neuroendocrine Tumors; Nivolumab; Progression-Free Survival; Temozolomide | 2023 |
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Topics: Humans; Lung Neoplasms; Neuroendocrine Tumors; Nivolumab; Progression-Free Survival; Temozolomide | 2023 |
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Topics: Humans; Lung Neoplasms; Neuroendocrine Tumors; Nivolumab; Progression-Free Survival; Temozolomide | 2023 |
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumo | 2022 |
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumo | 2022 |
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumo | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.
Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Somatostatin; Temozolomide | 2022 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms?
Topics: Humans; Neuroendocrine Tumors; Nivolumab; Temozolomide | 2023 |
Prospective Evaluation of
Topics: Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methylat | 2023 |
Prospective Evaluation of
Topics: Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methylat | 2023 |
Prospective Evaluation of
Topics: Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Humans; Methylat | 2023 |
Aggressive pituitary tumors (PitNETs).
Topics: Adenoma; Carcinoma; Humans; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide | 2023 |
Aggressive pituitary tumors (PitNETs).
Topics: Adenoma; Carcinoma; Humans; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide | 2023 |
Aggressive pituitary tumors (PitNETs).
Topics: Adenoma; Carcinoma; Humans; Neuroendocrine Tumors; Pituitary Neoplasms; Temozolomide | 2023 |
Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Topics: Adult; Aged; Capecitabine; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mutation; Neuroendoc | 2023 |
Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Topics: Adult; Aged; Capecitabine; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mutation; Neuroendoc | 2023 |
Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
Topics: Adult; Aged; Capecitabine; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mutation; Neuroendoc | 2023 |
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Middle Aged; Neuroendocrine Tu | 2023 |
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Middle Aged; Neuroendocrine Tu | 2023 |
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Middle Aged; Neuroendocrine Tu | 2023 |
Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide.
Topics: Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Dacarbazine; Humans; Lung Neoplasms; Neuroendocrin | 2023 |
Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide.
Topics: Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Dacarbazine; Humans; Lung Neoplasms; Neuroendocrin | 2023 |
Treatment of inoperable large cell neuroendocrine lung cancer with single agent temozolomide.
Topics: Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Dacarbazine; Humans; Lung Neoplasms; Neuroendocrin | 2023 |
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Topics: Female; Humans; Male; Neuroendocrine Tumors; Pituitary Diseases; Pituitary Neoplasms; Retrospective | 2023 |
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Topics: Female; Humans; Male; Neuroendocrine Tumors; Pituitary Diseases; Pituitary Neoplasms; Retrospective | 2023 |
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Topics: Female; Humans; Male; Neuroendocrine Tumors; Pituitary Diseases; Pituitary Neoplasms; Retrospective | 2023 |
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2020 |
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2020 |
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2020 |
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Age | 2020 |
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Age | 2020 |
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Age | 2020 |
Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration.
Topics: Capecitabine; Duration of Therapy; Fluorouracil; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration.
Topics: Capecitabine; Duration of Therapy; Fluorouracil; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration.
Topics: Capecitabine; Duration of Therapy; Fluorouracil; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administ
Topics: Capecitabine; Dacarbazine; Duration of Therapy; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administ
Topics: Capecitabine; Dacarbazine; Duration of Therapy; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administ
Topics: Capecitabine; Dacarbazine; Duration of Therapy; Humans; Neuroendocrine Tumors; Temozolomide | 2020 |
Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Middle Aged; Neoa | 2020 |
Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Middle Aged; Neoa | 2020 |
Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male; Middle Aged; Neoa | 2020 |
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Female; Hepate | 2020 |
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Female; Hepate | 2020 |
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Female; Hepate | 2020 |
Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cryopreservation; Drug Screening Assays, Antitumor; Everoli | 2021 |
Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cryopreservation; Drug Screening Assays, Antitumor; Everoli | 2021 |
Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cryopreservation; Drug Screening Assays, Antitumor; Everoli | 2021 |
Nearing the Summit: Associating Liver Partitioning and Portal Ligation for Staged Hepatectomy (ALPPS) in Progressive Carcinoid Disease.
Topics: Antineoplastic Agents; Capecitabine; Disease Progression; Female; Hepatectomy; Humans; Liver; Liver | 2020 |
Nearing the Summit: Associating Liver Partitioning and Portal Ligation for Staged Hepatectomy (ALPPS) in Progressive Carcinoid Disease.
Topics: Antineoplastic Agents; Capecitabine; Disease Progression; Female; Hepatectomy; Humans; Liver; Liver | 2020 |
Nearing the Summit: Associating Liver Partitioning and Portal Ligation for Staged Hepatectomy (ALPPS) in Progressive Carcinoid Disease.
Topics: Antineoplastic Agents; Capecitabine; Disease Progression; Female; Hepatectomy; Humans; Liver; Liver | 2020 |
A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Hum | 2021 |
A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Hum | 2021 |
A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Hum | 2021 |
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Italy; Neuroendocrine Tumors; | 2021 |
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Italy; Neuroendocrine Tumors; | 2021 |
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Italy; Neuroendocrine Tumors; | 2021 |
Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Leucovorin; Neur | 2021 |
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Leucovorin; Neur | 2021 |
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Leucovorin; Neur | 2021 |
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxo | 2022 |
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxo | 2022 |
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxo | 2022 |
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Neuroendocrine T | 2021 |
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Neuroendocrine T | 2021 |
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Neuroendocrine T | 2021 |
Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Humans | 2022 |
Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Humans | 2022 |
Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Humans | 2022 |
Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.
Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Alkylating; Biomarkers, | 2017 |
Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.
Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Alkylating; Biomarkers, | 2017 |
Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.
Topics: AC133 Antigen; Aged; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents, Alkylating; Biomarkers, | 2017 |
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; | 2017 |
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; | 2017 |
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; | 2017 |
Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combination | 2018 |
Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combination | 2018 |
Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combination | 2018 |
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Fe | 2018 |
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Fe | 2018 |
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Fe | 2018 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabin | 2018 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabin | 2018 |
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabin | 2018 |
Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Emboli | 2018 |
Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Emboli | 2018 |
Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Emboli | 2018 |
Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Neuroendocrine T | 2019 |
Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Neuroendocrine T | 2019 |
Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Neuroendocrine T | 2019 |
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cape | 2019 |
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Female; Humans; Male; Middle | 2019 |
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Female; Humans; Male; Middle | 2019 |
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Female; Humans; Male; Middle | 2019 |
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Cabergoline; Combined Modality Therapy; Cytoreduction Surgical Pr | 2019 |
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Cabergoline; Combined Modality Therapy; Cytoreduction Surgical Pr | 2019 |
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Cabergoline; Combined Modality Therapy; Cytoreduction Surgical Pr | 2019 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Humans; Male; M | 2020 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Humans; Male; M | 2020 |
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Humans; Male; M | 2020 |
Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chromosome I | 2019 |
Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chromosome I | 2019 |
Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chromosome I | 2019 |
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineo | 2019 |
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineo | 2019 |
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineo | 2019 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Ther | 2014 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Ther | 2014 |
Pancreatic neuroendocrine tumors: does chemotherapy work?
Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Ther | 2014 |
Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Daca | 2014 |
Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Daca | 2014 |
Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Daca | 2014 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Dif | 2014 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Dif | 2014 |
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Dif | 2014 |
Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2015 |
Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2015 |
Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2015 |
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoradiotherapy; Dacarbaz | 2016 |
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoradiotherapy; Dacarbaz | 2016 |
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoradiotherapy; Dacarbaz | 2016 |
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free | 2016 |
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free | 2016 |
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free | 2016 |
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2016 |
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2016 |
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2016 |
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2016 |
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2016 |
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2016 |
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Mal | 2017 |
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Mal | 2017 |
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Mal | 2017 |
BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells.
Topics: Antineoplastic Agents; Benzodiazepines; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Pr | 2017 |
BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells.
Topics: Antineoplastic Agents; Benzodiazepines; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Pr | 2017 |
BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells.
Topics: Antineoplastic Agents; Benzodiazepines; Capecitabine; Cell Cycle Proteins; Cell Line, Tumor; Cell Pr | 2017 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2008 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2008 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2008 |
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Topics: Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Disease-Free Survival; Female; Huma | 2009 |
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Topics: Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Disease-Free Survival; Female; Huma | 2009 |
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Topics: Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Disease-Free Survival; Female; Huma | 2009 |
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Di | 2012 |
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Di | 2012 |
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Di | 2012 |
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; D | 2012 |
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; D | 2012 |
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; D | 2012 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Flu | 2013 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Flu | 2013 |
Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Flu | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb | 2013 |
Oral regimen for metastatic neuroendocrine tumours.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Daca | 2006 |
Oral regimen for metastatic neuroendocrine tumours.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Daca | 2006 |
Oral regimen for metastatic neuroendocrine tumours.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Daca | 2006 |
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.
Topics: Aged; Bronchial Neoplasms; Carcinoid Tumor; Dacarbazine; Female; Hematologic Diseases; Humans; Male; | 2007 |
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.
Topics: Aged; Bronchial Neoplasms; Carcinoid Tumor; Dacarbazine; Female; Hematologic Diseases; Humans; Male; | 2007 |
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.
Topics: Aged; Bronchial Neoplasms; Carcinoid Tumor; Dacarbazine; Female; Hematologic Diseases; Humans; Male; | 2007 |
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Female; Her | 2007 |
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Female; Her | 2007 |
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Female; Her | 2007 |